Late breaking presentation at american heart association annual meeting of landmark phase 3 trial of rexlemestrocel-l in chronic heart failure

Trial results highlighted reduction in cardiovascular mortality, heart attacks and strokes, with greatest effect seen in setting of inflammation
MESO Ratings Summary
MESO Quant Ranking